Intelligence / Healthtech / New Clinical Trials / Ribocure Pharmaceuticals AB
Clinicaltrial registered20 Oct 2026
Ribocure Pharmaceuticals AB
20 Oct 2026: Trial registered · RBD1119 in Coronary Artery Disease (CAD). Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 20 Oct 2026
- Title
- RBD1119 in Coronary Artery Disease (CAD)
- Conditions
- Stable Coronary Artery Disease
- Phase
- Phase 2
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- Poland, Sweden
- Country
- Poland
- Reference
- NCT07884136
- Location
- Poland, Sweden
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Ribocure Pharmaceuticals AB
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Poland
New Clinical Trials
17 NovAstraZenecatrial registered · A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical12 NovNovo Nordisk A/Strial registered · AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or BothClinical10 NovBoehringer Ingelheimtrial registered · A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.